A multicenter, open label, phase I / II study to evaluate safety, pharmacokinetics and efficacy of BIBF 1120 in comparison with oral sorafenib for advanced hepatocellular carcinoma patients. - BIBF 1120 in HCC

Boehringer Ingelheim0 个研究点目标入组 1 人开始时间: 待定最近更新: 2024年4月29日

适应症

试验速览

阶段: 2 期
状态: 已完成
发起方: Boehringer Ingelheim
入组人数: 1

研究概览入排标准研究者记录与标识符相似试验

研究概览

简要总结

暂无简介。

研究设计

研究类型: Interventional

入排标准

年龄范围: 18 至 99（—）

入选标准

•1. HCC, either histologically/cytologically confirmed diagnosis or clinically diagnosis by ;AASLD criteria, which is not amenable to local therapy (RFA, PEI, RT, TACE);2. Age 18 years or older;3. ECOG performance score of 2 or less;4. Child-Pugh score A (score 5-6);5. At least one measurable lesion according to RECIST 1.0 (this criterion is limited to phase II only);6. In case a measurable lesion was previously treated by loco-regional therapy (RFA, PEI, TACE or RT), this lesion must be documented as progression according to RECIST 1.0 by CT or MRI (this criterion is limited to phase II only).;7. Time interval from last local therapy more than 4 weeks prior to start of study;treatment;8. Written informed consent consistent with ICH-GCP and local legislation

排除标准

•1. Prior systemic therapy for metastatic/unresectable HCC (for phase II) ;2. More then one line of prior systemic therapy for metastatic/unresectable HCC (for ;phase I);3. Fibrolamellar HCC;4. Uncontrolled or refractory ascites by adequate medical therapy;5. Bilirubin greater than 1.5 times ULN;6. AST or ALT greater than 2 times ULN;7. Hepatic encephalopathy more than grade 1 according to Child-Pugh criteria;8. Prothrombin time international normalized ratio greater than 2.3, or prothrombin ;time more than 6 seconds prolonged than control;9. Absolute neutrophil count less than 1000/µL;10. Platelet count less than 60000/µL;11. Hemoglobin less than 9 g/dL;12. Serum creatinine greater than 1.5 times ULN;13. Proteinuria of CTCAE grade 2 or greater;14. Variceal bleeding within 6 months prior to start of study treatment;15. History of major thrombotic (except portal vein thrombosis) or clinically relevant ;major bleeding event in the past 6 months;16. Known inherited predisposition to bleeding or thrombosis ;17. Significant cardiovascular diseases (i.e. hypertension not controlled by medical ;therapy (blood pressure > 150/90 mmHg), unstable angina, history of myocardial ;infarction within the past 6 months, congestive heart failure > NYHA II, serious ;cardiac arrhythmia, pericardial effusion);18. Therapeutic anticoagulation (except low dose heparin and/or heparin flush as ;needed for maintenance of an indwelling intravenous device) or antiplatelet ;therapy (except for chronic low-dose therapy with acetylsalicylic acid <= 325mg ;per day);19. Last administration of systemic treatment for HCC within 4 weeks prior to start ;of study treatment or no recovery from any treatment related toxicity;20. Major surgery within 4 weeks prior to start of study treatment;21. Treatment with other investigational drugs concomitantly with this trial (except ;for present trial drug);22. Serious illness or concomitant non-oncological disease such as neurologic, ;psychiatric, infectious disease or active ulcers (gastro-intestinal tract, skin) or ;laboratory abnormality that may increase the risk associated with study ;participation or study drug administration and in the judgment of the ;investigator would make the patient inappropriate for entry into the study;23. Patients who are sexually active and unwilling to use a medically acceptable ;method of contraception (e.g. such as implants, injectables, combined oral ;contraceptives, some intrauterine devices or vasectomized partner for ;participating females, condomes for participating males) during the trial and for ;at least twelve months after end of active therapy;24. Current alcohol abuse or drug abuse that would limit patient ability to comply ;with protocol;25. Symptomatic CNS metastasis;26. Life expectancy less than 12 weeks;27. Patient unable to take oral medication;28. Gastrointestinal disorders or abnormalities that would interfere with absorption ;of the study drug;29. Pregnancy or breast feeding;30. Patient unable to comply with the protocol;31. Other malignancy within the past three years other than basal cell skin cancer, ;or carcinoma in situ of the cervix;32. Hypersensitivity to active substance or to any of the excipients of both BIBF ;1120 or sorafenib

研究者

发起方

Boehringer Ingelheim

相似试验

进行中（未招募）

1 期

Clinical trial conducted in two parts: the first (phase I) to find out the safe dose of BIBF 1120 in the treatment of patients with liver cancer and the second part (phase II) to compare this dose of BIBF 1120 with Sorafenib in the treatment of hepatocellular carcinoma (liver cancer)Histologically or cytologically confirmed hepatocellular carcinoma not amenable to local therapy with adequate renal, hematological and liver paramenters with Child-Pugh score 5-6, in 1st line systemic therapy.

EUCTR2009-011925-14-ATBoehringer Ingelheim RCV GmbH & Co. KG132

进行中（未招募）

1 期

EUCTR2009-011925-14-DEBoehringer Ingelheim Pharma GmbH & Co. KG132

进行中（未招募）

1 期

EUCTR2009-011925-14-NLBoehringer Ingelheim bv132

进行中（未招募）

1 期

Phase I/II comparison of efficacy and safety of BBF 1120 and sorafenib in patients with advanced hepatocellular carcinomaHistologically or cytologically confirmed hepatocellular carcinoma not amenable to local therapy with adequate renal, hematological and liver paramenters with Child-Pugh score 7 or less, in 1st line systemic therapy. Note for phase II only liver function group I patients with Child Pugh A will be enrolledMedDRA version: 16.1 Level: LLT Classification code 10049010 Term: Carcinoma hepatocellular System Organ Class: 100000004864

EUCTR2009-011925-14-GBBoehringer Ingelheim170

招募中

1 期

M1774 in Combination with Cemiplimab in Participants with Non-Squamous NSCLC (DDRiver NSCLC 322)on-Squamous Non-Small Cell Lung Cancer

JPRN-jRCT2031230332Ishii Kyoko25